Novartis AG (NVSEF)
117.60
+2.27
(+1.97%)
USD |
OTCM |
Jun 06, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 232.26B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 19.11% |
| Valuation | |
| PE Ratio | 18.40 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.452 |
| Price to Book Value | 6.053 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 3.977 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.768 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 22.69% |
Profile
| Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue. |
| URL | https://www.novartis.com |
| Investor Relations URL | https://www.novartis.com/investors |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Jul. 17, 2025 |
| Last Earnings Release | Apr. 29, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 11, 2025 |
Ratings
Profile
| Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue. |
| URL | https://www.novartis.com |
| Investor Relations URL | https://www.novartis.com/investors |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Jul. 17, 2025 |
| Last Earnings Release | Apr. 29, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 11, 2025 |